Exclusively for Health Care Professionals. Stay up to date on Novo Nordisk diabetes products: Victoza®, Levemir®, NovoMix®, NovoRapid® and Devices, and read about current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients.
Overview
NovoSeven®
270 µg/kg dose
Room temperature stable
8 mg vial
Management
Blood coagulation
Key papers
Treatment guidelines
Services & links
WFH patients'
leaflet
Patient story
Congenital haemophilia
Acquired haemophilia
Factor VII deficiency
Glanzmann's
thrombasthenia
Overview
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency) in adults
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Norditropin®
Norditropin® FlexPro®
Norditropin NordiFlex®
NordiFlex PenMate®
NordiPen® with Norditropin® SimpleXx®
NordiPenMate®
Norditropin® NordiLet®
NovoFine®
NordiNet® (outcomes registry)
NordiScience® (HCP support)
NordiCare® (Patient support)
Our partnership with Save the Children
Testimonials
Overview
Introduction
Activelle®
Eviana®
Novofem®
Estrofem®
Vagifem®
Convenience & compliance
Our history in HRT
Introduction
Symptoms & complaints
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
Log out to deactivate menu
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Do you have a recent master degree, and do you want a successful career in one of the world's leading pharmaceutical companies? If yes, then the Novo Nordisk Graduate Programme is what you are looking for.
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries.
Novo Nordisks B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Superflow™ technology makes injection quicker and easier, reducing the effort needed to inject insulin.
Improved insulin flow potentially reduces the time to administer a dose of insulin.
Less effort on injection may reduce skin-tissue damage that can occur with needle movement during injection.
APROM ID# 3126. June 2011.
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries.
 | Novo Nordisk in the USA |
 | Novo Nordisk in Denmark |
Or choose:
